Literature DB >> 11822004

Gastroesophageal reflux disease and Barrett's esophagus.

H Koop1.   

Abstract

Gastroesophageal reflux disease (GERD) is a common clinical problem. More frequent and extended acidic reflux episodes are characteristic of GERD, although substantial (nonacid) reflux per se is also observed in control individuals. Helicobacter pylori may protect some people from reflux disease, but others do not experience deterioration of GERD as a result of H. pylori eradication, for reasons so far unknown. Medical treatment, preferably with proton-pump inhibitors, is well established and is also recommended in endoscopy-negative forms of the disease, although the efficacy is less marked in comparison with erosive esophagitis. Surgery has emerged as an alternative to medical therapy, but the long-term results do not now appear to be as promising as was initially claimed. A number of new endoscopic techniques for the treatment of GERD have been developed, but the future for these is unclear. Barrett's esophagus develops in some patients with GERD for unknown reasons, and surveillance should be carried out in these patients due to the risk of subsequent malignant transformation. Several new approaches have been developed for detecting premalignant conditions, but these need to be investigated further. Ablative techniques are still under intensive investigation, and appear to be promising, at least in a subset of patients, although they are not devoid of major complications. Whether antireflux therapy, irrespective of the method used, can slow down the development of cancer is still an intriguing and clinically important question.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11822004     DOI: 10.1055/s-2002-19851

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  4 in total

Review 1.  Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.

Authors:  Malcolm Robinson; John Horn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Helicobacter pylori induces apoptosis in Barrett's-derived esophageal adenocarcinoma cells.

Authors:  Andrew D Jones; Kathy D Bacon; Blair A Jobe; Brett C Sheppard; Clifford W Deveney; Michael J Rutten
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

3.  High dose rate brachytherapy (HDR-BT) in locally advanced oesophageal cancer. Clinic response and survival related to biological equivalent dose (BED).

Authors:  Maria C López Carrizosa; P Maria Samper Ots; A Rodríguez Pérez; A Sotoca; J Sáez Garrido; M M de Miguel
Journal:  Clin Transl Oncol       Date:  2007-06       Impact factor: 3.340

4.  Barrett's oesophagus and adenocarcinoma.

Authors:  Christine P J Caygill; Anthony Watson; Pierre Lao-Sirieix; Rebecca C Fitzgerald
Journal:  World J Surg Oncol       Date:  2004-05-07       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.